Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation

Last updated: March 18, 2022
Sponsor: Fundacin Biomedica Galicia Sur
Overall Status: Active - Recruiting

Phase

4

Condition

Open Heart Surgery

Cardiac Surgery

Treatment

N/A

Clinical Study ID

NCT05283356
REAC-TAVI 2
2021-003927-13
  • Ages > 18
  • All Genders

Study Summary

The optimal pharmacological therapy after transcatheter aortic valve implantation (TAVI) to prevent valve thrombosis and reduce thromboembolic complications without significantly increasing the risk of bleeding is not yet fully defined and constitutes an important unmet clinical need. Recently, single antiplatelet therapy (SAPT) with Aspirin has been increasingly adopted to avoid bleeding early after TAVI compared with dual antiplatelet therapy. However, TAVI population is affected by a diversity of chronic pathologies that increase the risk of post-TAVI ischemic complications. Stroke is prevalent, especially peri- and early post-TAVI (<1-8% in the 1st year). Although peri-TAVI myocardial infarction (MI) is rare (1-3%), concomitant coronary artery disease (CAD), diabetes mellitus (DM), and peripheral vascular disease (PVD), is very frequent in the TAVI population, affecting around 30-70% of patients. In patients with CAD, the need to re-access the coronary arteries after TAVI is challenging and can be hampered by the trancatheter valve struts.

This is critical in TAVI patients with an acute coronary syndrome and in younger patients with long-life expectancy after TAVI. The use of a P2Y12 inhibitor provides significant ischemic protection in the in the coronary, cerebral and peripheral vascular territories compare to Aspirin. The use of a P2Y12 inhibitor as antiplatelet treatment can decrease the need for new coronary revascularizations and reduce the incidence of thromboembolic complications after TAVI.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures.
  2. Adult patients (more than 18 years) with ability to understand and accept theparticipation in the clinical trial.
  3. Patients with degenerative symptomatic severe aortic stenosis (AS) accepted for TAVIwith any of the commercial approved TAVI devices after evaluation of the Heart Team ofeach center,and with at least one of the following comorbidities:
  4. Diabetes Mellitus, the current WHO diagnostic criteria for diabetes should bemaintained - fasting plasma glucose ≥ 7.0mmol/l (126 mg/dl) or 2-h plasma glucose ≥ 11.1mmol/l (200mg/dl), or under treatment with an oral hypoglycemic or insulin.
  5. Prior coronary artery disease (STEMI, NSTEMI, stable angina, or others)documented by invasive or non-invasive ischemia screening tests or imaging study.
  6. Prior peripheral arterial disease documented by invasive or non-invasive ischemiascreening tests or imaging study.
  7. Successful TAVI performed by any vascular access.
  8. Patients who are not participating in any other clinical trial or research study (registries allowed).

Exclusion

Exclusion Criteria:

  1. Patients under chronic oral anticoagulation for any specific pathology.
  2. Patients that cannot undergo a regimen of single antiplatelet therapy after TAVI.
  3. History of overt major bleeding or intracranial hemorrhage.
  4. Active pathological bleeding.
  5. History of ischemic stroke within the last 30 days prior TAVI.
  6. Patients with documented severe hepatic insufficiency.
  7. Known pregnancy, breast-feeding, or intend to become pregnant during the study period.
  8. Concomitant oral or intravenous therapy with potent inhibitors of cytochrome P450 3A (CYP3A) that cannot be suspended during the study.
  9. Patients randomized in another clinical trial with an investigational product ordevice over the past 30 days.
  10. Patients who cannot attend follow-up visits scheduled in the study.
  11. History of allergic reactions or intolerance to Ticagrelor or Aspirin or any of theexcipients.

Study Design

Total Participants: 1206
Study Start date:
January 21, 2022
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • Hospital Alvaro Cunqueiro

    Vigo, Pontevedra 36312
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.